Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-10-06

FDA Approved: BUSPIRONE HYDROCHLORIDE — Supplemental Application (Rising Pharma Holdings, Inc.)

View source ↗

Summary

FDA approved a supplemental application for buspirone hydrochloride from Rising Pharma Holdings, Inc., allowing a change to an existing generic product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buspirone hydrochloride (buspirone hydrochloride)

Snippet

SUPPL AP for BUSPIRONE HYDROCHLORIDE (BUSPIRONE HYDROCHLORIDE)